Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines of Formula I:
wherein X, Y, Z, L, A, R5, n, m, and r are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
206 Citations
36 Claims
-
1. A compound of Formula I:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N.
-
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is O.
-
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is cyano.
-
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1, R2, and R3 are each H.
-
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R5 is fluorine.
-
7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
-
8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1.
-
9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein r is 1.
-
10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;
- each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R7 substituents.
-
11. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein each R7 is independently selected from halo, cyano, C1-6 alkyl, C1-6 haloalkyl, —
- C(═
O)Rb, and —
C(═
O)NReRf;
wherein said C1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected Rg groups.
- C(═
-
12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
-
X is N; Z is N; L is O; R1, R2, and R3 are each H; each R5 is fluorine; A is C3-10 cycloalkyl, C2-10 heterocycloalkyl, C6-10 aryl, or C1-10 heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R7 substituents; each R7 is independently selected from halo, cyano, nitro, C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4-alkyl, C2-10 heterocycloalkyl, C2-10 heterocycloalkyl-C1-4-alkyl, —
ORa, —
SRa, —
S(═
O)Rb, —
S(═
O)2Rb, —
S(═
O)2NReRf, —
C(═
O)Rb, —
C(═
O)ORa, —
C(═
O)NReRf, —
OC(═
O)Rb, —
OC(═
O)NReRf, —
NReRf, —
NRcC(═
O)Rd, —
NRcC(═
O)ORd, —
NRcC(═
O)NRd, —
NRcS(═
O)2Rd, and —
NRcS(═
O)2NReRf;
wherein said C1-6 alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4-alkyl, C2-10 heterocycloalkyl, C2-10 heterocycloalkyl-C1-4-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rg is independently selected from halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, —
ORa1, —
S(═
O)2Rb1, —
S(═
O)2NRe1Rf1, —
C(═
O)Rb1, —
C(═
O)ORa1, —
C(═
O)NRe1Rf1, —
OC(═
O)Rb1, —
OC(═
O)NRe1Rf1, —
NRc1C(═
O)Rd1, —
NRc1C(═
O)ORd1, —
NRc1C(═
O)NRd1, —
NRc1S(═
O)2Rd1, and —
NRc1S(═
O)2NRe1Rf1;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected Rh groups;each Ra, Rc, Rd, and Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl, wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rg groups; each Rb is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rf is independently selected from H and C1-6 alkyl; each Ra1, Rc1, Rd1, and Re1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rh groups; andeach Rb1 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl optionally substituted by 1, 2, 3, or 4 independently selected Rh groups;m is 1; n is 0, 1, or 2; and r is 1.
-
-
13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
-
X is N; Z is N; L is O; R1, R2, and R3 are each H; each R5 is fluorine; A is C6-10 aryl or C1-10 heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R7 substituents; each R7 is independently selected from halo, cyano, C1-6 alkyl, C1-6 haloalkyl, —
ORa, —
S(═
O)2Rb, —
S(═
O)2NReRf, —
C(═
O)Rb, —
C(═
O)ORa, and —
C(═
O)NReRf;
wherein said C1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rg is independently selected from halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C2-7 heterocycloalkyl, —
ORa1, —
C(═
O)NRe1Rf1, and —
NRe1Rf1;
wherein said C1-6 alkyl and C2-7 heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected Rh groups;each Ra and Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rb is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rf is independently selected from H and C1-6 alkyl; each Re1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl, wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rh groups; each Rf1 is independently selected from H and C1-6 alkyl; m is 1; n is 0, 1, or 2; and r is 1.
-
-
14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
-
X is N; Z is N; L is O; Y is cyano; R1, R2, and R3 are each H; each R5 is fluorine; A is C6-10 aryl, optionally substituted with 1, 2, 3, 4, or 5 independently selected R7 substituents; each R7 is independently selected from halo, cyano, C1-6 alkyl, C1-6 haloalkyl, —
C(═
O)Rb, and —
C(═
O)NReRf;
wherein said C1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rg is independently selected from halo, cyano, C1-6 alkyl, C2-7 heterocycloalkyl, —
C(═
O)NRe1Rf1, and —
NRe1Rf1;
wherein said C1-6 alkyl and C2-7 heterocycloalkyl is optionally substituted with 1 or 2 independently selected Rh groups;each Rh is independently selected from halo, C1-4 alkyl, and C1-4 alkoxy; each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl, wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rg groups; each Rf is independently selected from H and C1-6 alkyl; each Rb is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Re1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl, wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rh groups; each Rf is independently selected from H and C1-6 alkyl; m is 1; n is 0 or 1; and r is 1.
-
-
15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
-
X is N; Z is N; L is O; Y is cyano; R1, R2, and R3 are each H; each R5 is fluorine; A is phenyl, optionally substituted with 1, 2, 3, 4, or 5 independently selected R7 substituents; each R7 is independently selected from halo, cyano, C1-6 alkyl, C1-6 haloalkyl, —
C(═
O)b, and —
C(═
O)NReRf;
wherein said C1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Rg is independently selected from halo, cyano, C1-6 alkyl, C2-7 heterocycloalkyl, —
C(═
O)NRe1Rf1, and —
NRe1Rf1;
wherein said C1-6 alkyl and C2-7 heterocycloalkyl is optionally substituted with 1 or 2 independently selected Rh groups;each Rh is independently selected from halo, C1-4 alkyl, and C1-4 alkoxy; each Re is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl, wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rg groups; each Rf is independently selected from H and C1-6 alkyl; each Rb is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl;
wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected Rg groups;each Re1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl, wherein said C1-6 alkyl, C3-7 cycloalkyl, and C2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rh groups; each Rf1 is independently selected from H and C1-6 alkyl; m is 1; n is 0 or 1; and r is 1.
-
-
16. The compound of claim 1, wherein said compound is a compound of Formula II:
-
17. The compound of claim 1, wherein said compound is a compound of Formula III:
-
18. A compound of claim 1, selected from:
-
4-[4-(3,5 -difluorophenoxy)piperidin-1- yl]-3-[4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-[4-(3-chloro-5-fluorophenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-{4-[3-fluoro-5-(trifluoromethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-4-[4-(3,4,5-trifluorophenoxy)piperidin-1-yl]butanenitrile; 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-4-[4-(2,3,5-trifluorophenoxy)piperidin-1-yl]butanenitrile; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluorobenzonitrile; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N-methylbenzamide; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N,N-dimethylbenzamide; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-N-ethyl-5-fluorobenzamide; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-N-cyclopropyl-5-fluorobenzamide; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N-isopropylbenzamide; N-(2-cyanoethyl)-3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}peperidin-4-yl)oxy]-5-fluorobenzamide; 4-{4-[3-fluoro-5-(pyrrolidin-1-ylcarbonyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; N-(3-amino-3-oxopropyl)-3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl) oxy]-5-fluorobenzamide; N-(tert-butyl)-3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluorobenzamide; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N-(2-morpholin-4-ylethyl)benzamide; 4-{4-[3-fluoro-5-(piperidin-1-ylcarbonyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-{4-[3-fluoro-5-(morpholin-4-ylcarbonyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-(4-{3-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-[4-(3-{[cyclopropyl(methyl)amino]methyl}-5-fluorophenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-{4-[3-(azetidin-1-ylmethyl)-5-fluorophenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-(4-{3-[(cyclobutylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-{4-[3-fluoro-5-(pyrrolidin-1-ylmethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-{4-[3-fluoro-5-(piperidin-1-ylmethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-{4-[3-fluoro-5-(morpholin-4-ylmethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1H-pyrazol-1-yl]butanenitrile; 4-(4-{3-[(3,3-difluoropyrrolidin-1-yl)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-[4-(3-fluoro-5-{[2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-[4-(3-fluoro-5-{[(2-methoxyethyl)amino]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}-3-fluoropiperidin-4-yl)oxy]-5-fluorobenzonitrile; and 4-[3-fluoro-4-(3-fluoro-5-{[2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; or a pharmaceutically salt of any of the aforementioned.
-
-
19. A compound of claim 1, selected from:
-
4-[4-(3-fluoro-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-[4-(3-fluoro-5-{[(2S)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; 4-[3-fluoro-4-(3-fluoro-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; and 4-[3-fluoro-4-(3-fluoro-5-{[(2S)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; or a pharmaceutically salt of any of the aforementioned.
-
-
20. The compound according to claim 1, wherein the compound is the (R)-enantiomer, or a pharmaceutically acceptable salt thereof.
-
21. The compound according to claim 1, wherein the compound is the (S)-enantiomer, or a pharmaceutically acceptable salt thereof.
-
22. A composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
-
23. A method of inhibiting an activity of JAK1 comprising contacting JAK1 with a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
-
24. A method according to claim 23, wherein said compound, or pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2.
-
25. A method of treating rheumatoid arthritis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
26. A method of treating psoriasis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.
-
27. A method of treating lymphoma, leukemia, or multiple myeloma in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
28. A method of treating polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
29. A method of treating myelofibrosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
30. A method of treating primary myelofibrosis (PMF) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
31. A method of treating organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
32. A method of treating polycythemia vera (PV) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
33. A method of treating essential thrombocythemia (ET) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N.
-
34. A compound which is 4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (35, 36)
-
35. The compound of claim 34, where the compound is (R)-4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.
-
36. The compound of claim 34, which is (S)-4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.
-
35. The compound of claim 34, where the compound is (R)-4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeIncyte Holdings Corporation And Incyte Corporation
-
Original AssigneeIncyte Corporation
-
InventorsRodgers, James D., Zhu, Wenyu, Glenn, Joseph
-
Primary Examiner(s)Moore, Susanna
-
Application NumberUS13/300,137Publication NumberTime in Patent Office1,278 DaysField of Search544/280, 514/265.1US Class Current514/265.1CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 1/16 for liver or gallbladder di...A61P 13/12 of the kidneysA61P 17/00 Drugs for dermatological di...A61P 17/04 AntipruriticsA61P 17/06 AntipsoriaticsA61P 19/00 Drugs for skeletal disordersA61P 19/02 for joint disorders, e.g. a...A61P 19/04 for non-specific disorders ...A61P 19/08 for bone diseases, e.g. rac...A61P 19/10 for osteoporosisA61P 21/04 for myasthenia gravisA61P 25/00 Drugs for disorders of the ...A61P 29/00 Non-central analgesic, anti...A61P 3/10 for hyperglycaemia, e.g. an...A61P 35/00 Antineoplastic agentsA61P 35/02 specific for leukemiaA61P 37/00 Drugs for immunological or ...A61P 37/06 Immunosuppressants, e.g. dr...A61P 43/00 Drugs for specific purposes...A61P 5/14 : of the thyroid hormones, e....A61P 5/16 : for decreasing, blocking or...A61P 7/00 : Drugs for disorders of the ...A61P 9/00 : Drugs for disorders of the ...A61P 9/10 : for treating ischaemic or a...C07D 487/04 : Ortho-condensed systems